A 12-month, open label, flexible-dosage study of the safety/efficacy of CEP 10953 [armodafinil] in the treatment of excessive sleepiness associated with narcolepsy, obstructive sleep apnea/hypopnea syndrome, or chronic shift work sleep disorder.

Trial Profile

A 12-month, open label, flexible-dosage study of the safety/efficacy of CEP 10953 [armodafinil] in the treatment of excessive sleepiness associated with narcolepsy, obstructive sleep apnea/hypopnea syndrome, or chronic shift work sleep disorder.

Completed
Phase of Trial: Phase III

Latest Information Update: 06 Apr 2010

At a glance

  • Drugs Armodafinil (Primary)
  • Indications Circadian rhythm sleep disorders; Narcolepsy; Sleep apnoea syndrome
  • Focus Adverse reactions; Registrational
  • Sponsors Cephalon
  • Most Recent Events

    • 02 Mar 2010 Actual end date (Jul 2006) and actual number of patients (328) added as reported by ClinicalTrials.gov.
    • 18 Sep 2007 Status change
    • 09 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top